Here is a 2012 interview with Dr. Michael Callahan, who allegedly called up Sherpa in Jan. 2020 and told him to "spin up a team" on COVID
Plus a little data dump on the history of these "two old friends"
Video and First wave of links Promo code: Housatonic
ASSOCIATIONS - People
Dr. Darrell Ray Galloway (born 1946)
( Callahan and Galloway both worked on the 2011 Swine Flu response, albiet they each had different ideas of the optimal solution. Source : [HP008I][GDrive] ... "[Dr. Darrell Ray Galloway (born 1946)] kept an eye on Dr. Michael Vincent Callahan (born 1962) work, but he stayed focussed on building a drug, not a vaccine. The first step was to acquire a full genetic blueprint of the swine-flu virus," )
Galloway must have known Callahan since at least 2009, according to the RFK Jr Book "The Real Anthony Fauci" (2021) : "Dr. Robert Wallace Malone (born 1959) first met Dr. Darrell Ray Galloway (born 1946) in 2009 through Malone’s sometime business partner, [Dr. Darrell Ray Galloway (born 1946)], a CIA officer who formerly served in the US Navy and at one point held the post of director of JSTO in the [Defense Threat Reduction Agency, aka "DTRA"]. To Malone, Galloway introduced Callahan as a fellow CIA officer."
Robert Peter Kadlec (born 1957) ( ... )
ASSOCIATIONS - Events
Zika virus epidemic (2015-2016) ( Dr. Callahan was the President of the Zika Foundation, and involved in several Zika research efforts ... [HW008M][GDrive] )
The "Red Dawn" Group - ( Dozens of mentions in the "Red Dawn" emails, but curiously ommitted by NY Times as a person of interest on the email list - Source is available (downloadable) ss a text file (see [HN01Y9][GDrive] ) or as a PDF (see [HN01YA][GDrive] ) )
Previous timeline explored here:
Dr. Robert Malone on The Joe Rogan Experience, Dec. 31, 2021
“I’ve got many friends in the Intelligence Community. So I’m kind of a pretty deep insider in terms of the government.”
“There is a CIA Agent that I’ve co-published with in the past named Michael Callahan. He was in Wuhan in the fourth quarter of 2019. He called me from Wuhan on January 4th (2020).
From Unlimited Hangout, July 31, 2020
Dr. Michael Callahan was given a leave of absence from his senior executive role at United Therapeutics (UTHR) in the wake of the COVID-19 outbreak in Wuhan, China; sent there to assist colleagues handling mass infections of the novel coronavirus under his joint appointment at a Chinese sister hospital of the Massachusetts General Hospital/Harvard Medical School, where he has maintained a faculty appointment since 2005.
Soon, Callahan would be pouring through thousands of case studies emerging from the epicenter of the outbreak in Wuhan, examining patients in Singapore and briefing U.S. officials on the location of the next likely outbreak, according to NatGeo. The doctor marveled at the “magnificent infectivity” of the disease, which sits “like a little silent smart bomb in your community”.
The doctor’s strange fascination with viral infections and morbid titillation might well be attributed to the fact that he has dedicated his life to studying these microscopic killers. “Triple boarded” in internal medicine, infectious diseases and tropical medicine, Callahan, nevertheless also has a strong entrepreneurial streak, that drove him to launch no less than 11 companies and develop 8 patents.
Callahan’s nose for business came into play early on in the pandemic. After studying data from over 6,000 patient records from Wuhan, he reportedly detected a pattern that could point to a possible treatment using a low-cost and widely available ingredient of an “over-the-counter histamine-2 receptor antagonist called Famotidine”, more commonly known as the brand name Pepcid.
Malone, August 1, 2022, Trouble in Old Friend Paradise as described on CHD:
“I had a series of interactions with him (Callahan) subsequently until I became completely disillusioned and aware that he was lying to me almost constantly, including about things like whether or not the pathogen was engineered. So, I think I can certainly empathize, and understand why some might have these concerns.
Why would Callahan lie to Malone about the pathogen being engineered?
From the RFK Jr. Book “The Real Anthony Fauci”:
Malone and Callahan allegedly both independently discovered famotidine was a useful treatment for COVID.
Famotidine’s brand name is Pepcid AC, an antacid.
Pepcid AC study article on the NY Times. Whoops.
Is the NYT in the habit of just scrubbing articles off the internet?
No problem! I found it on Malone’s own scrubbed materials.
The first segment is describing DOMANE, a DTRA “supercomputer” program to find re-purposed drugs for “novel” viruses. 🤨
Then onto more of the vibe between these two and the famotidine discovery.
Dr. Robert Malone is an internationally recognized physician scientist (virology, immunology, molecular biology, and drug discovery) and is known as one of the original inventors of DNA and RNA Vaccination. Together with his partner, also a scientist, Dr. Malone co-founded and is president of RW Malone MD, LLC, where he serves as principal consultant. When the sequence of the novel coronavirus (now known as SARS-CoV-2) was publicly disclosed on January 10, Dr. Malone and his colleagues began volunteering their time to find an antiviral treatment, knowing that a successful vaccine licensure would be years away. They began applying advanced supercomputing tools to determine whether any FDA licensed drugs or other nutraceuticals might be used to treat COVID-19 disease. This work by the team has been entirely voluntary, performed as “open source” research aimed at finding a potential repurposed drug treatment for COVID-19 while also demonstrating the usefulness of the system developed in support of DTRA rapid medical countermeasure development objectives. The team chose to focus on a SARS-CoV-2 virus protein that has been overlooked by many large pharmaceutical companies; a protein involved in early stages of virus replication, and which also suppresses parts of the immune response to SARS-CoV-2 and other viruses. Of the top ranked drugs identified by applying the drug discovery system developed for DTRA, the team determined that famotidine had the most attractive combination of safety, cost, and pharmaceutical characteristics. The success of the system to identify and rapidly advance a repurposed drug candidate for treatment of COVID-19 disease has demonstrated the usefulness of the DTRA approach. Dr. Malone presented a summary of the findings and recommendations to Dr. Callahan and the ASPR. The mission of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) is to save lives and protect Americans from 21st century health security threats
editor’s note: DTRA’s DOMANE system ended up spitting out Remdesivir. Malone says he had nothing to do with that. His old college friend David Hone is quoted here.
Of course Remdesivir would pop up everywhere. Long predictively programmed.
In Baric Country as well.
Back to What About Bob and Mike! Sherpa continues:
Dr. Michael Callahan is a physician scientist that works as a infectious disease, mass casualty infection doctor at the Massachusetts General Hospital in Boston, MA, and who has developed block-buster anti-infective drugs for the U.S. Government and for Industry, has a joint clinical appointment at a sister hospital in China. Dr. Callahan also serves as a senior executive at United Therapeutics, a publicly traded company that is focused on pulmonary hypertension and oncology. Dr. Callahan is triple boarded in internal medicine, infectious disease, tropical medicine, and is one of the few Command physicians based in the United States who specialize in mass casualty infection therapies. Over the last 17 years, Dr. Callahan has managed treatment of over 1000 Ebola patients across five outbreaks in three countries and previously deployed to 3 bird flu outbreaks and the 2002-03 SARS outbreak in Hong Kong.
With the advent of the outbreak of a novel coronavirus infection during December 2019, Dr. Callahan was granted a leave of absence by United Therapeutics’ CEO Martine Rothblatt to travel to China to assist clinical colleagues in mass infection management of COVID 19 under his joint appointment. Unaware of the work by Dr. Malone, Dr. Callahan worked with Asian colleagues to analyze medical records from over 6,000 hospitalized patients, 1,100 of whom had severe disease. This analysis of clinical data revealed that about 600 of these patients were on antacid therapies, and were found to have relatively mild COVID-19 disease compared to others of similar age and health. The incidence of COVID-19 in China dropped quickly, and Dr. Callahan and colleagues were not able to start a clinical trial to test famotidine as a promising oral therapy for treating COVID-19 disease. Dr. Callahan was then recruited to serve as Special Advisor on COVID 19 to the *Assistant Secretary of Public Health Preparedness and Response (ASPR), U.S Dept of Health and Human Services during this pandemic, and his leave of absence from United Therapeutics was extended due to the pressing emergency. Since appointment, has been working within the office of the Assistant Secretary to assist policy and management decisions while also lending his experience on the front lines in intensive care units across the country.
*Bob doesn’t mention who that is but it’s this dude:
Dr. Malone presented a summary of the team findings and recommendations to the ASPR on 18 March 2020. Both Dr. Callahan and Dr. Malone were previously unaware of each other’s work and agreed to collaborate on this project. As old friends, it is not the first time that they have worked to “save the world”. With convergence of these two independent discoveries, Feinstein/Northwell Health system was contacted to explore the possibility of performing well controlled clinical trials within the Northwell hospital system. Northwell hospital system agreed that this repurposed drug candidate worthy of rigorous evaluation of activity in randomized clinical trials. Because New York decided that the standard of care for hospitalized COVID-19 patients was to include hydroxychloroquine, this was added to the study arms to ensure enrollment of patients and comply with bioethical requirements for inclusion of standard of care in clinical trial designs.
Dr. Malone then wrote the initial clinical protocol. This was reviewed and edited by Dr. Robert Malone together with Drs. Martin Lesser, a biostatician and Joe Conigliary, a general internal medicine doctor within the Northwell hospital system. Robert was also the primary technical author writing the federal funding contract, which was subsequently funded by BARDA for 0ver 20 million dollars, three days later, to perform this clinical trial. Under this contract, Alchem Laboratories is prime contractor and Northwell health system became a sub-contractor for the BARDA award for advancement of this drug.
The volunteer team includes Dr. Joshua Patel of Molecular Forecasting, Dr. Gideon Shapiro, and Dr. Jill Glasspool Malone. We are grateful for this team and what they have accomplished.
About RW Malone MD, LLC
Alrighty, let’s leave it there for now.
We will explore Alchem Labs a bit more soon.
To do list:
Wrap up Astrid/Cole.
McGill Case Study #1, MKUltra
Alchem, Vapor Bar, and famotidine trials
Sage Hana: You are doing so much excellent work. And we (excluding the bots) appreciate it. You are keeping us sharp and focused and "in the game," which is not a game at all. It is history in the making; one moment after another. You are courageous, and smart, and funny. And you are helping write the history books that our children and grandchildren and those who follow them, will read. Bravo Zulu, Sage Hana. Bravo Zulu.
I smell a bad smell .... rats 🐀 or skunks 🦨 ... who cares it smells cause they have maimed and killed people. Untested Jabs to pregnant women, jabs in kids vaccine schedules... where do I stop ... never stop resist, it’s a culling and maybe more nefarious reasons .... but it’s ok it’s for the greater good so our government stays leaps and bounds in front of other countries. Government contracts with smart people is just fine 🤥🥲🤬